FDA approves lisocabtagene maraleucel (liso-cel or JCAR-017) a CAR-T cell therapy for relapsed or refractory large B-cell lymphoma
LLS may be able to help pay your insurance premiums and co-pays if you are in active treatment or are being monitored for watch and wait or follow up care.
Learn more about the CLL fund.
For details on what’s covered and how to apply, click here: https://www.lls.org/support/financial-support/co-pay-assistance-program
Related posts
